Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024
Stock Information for Spero Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.